Global Iron Chelation Drug Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Iron Chelation Drug market size was valued at US$ 444 million in 2024 and is forecast to a readjusted size of USD 431 million by 2031 with a CAGR of -0.4% during review period.
In a healthy body, when the stores of iron are sufficient, the intestines reduce the absorption of this mineral from food and drink to prevent its levels from rising too high. People with iron overload disorders absorb more iron than usual from food or supplements. The body cannot excrete the extra iron fast enough, so it continues to build up. The body stores it in organ tissue, mainly in the liver, as well as the heart and the pancreas. There are several types of iron overload disorder. Hereditary hemochromatosis is a primary condition that has a genetic component. People can also have secondary hemochromatosis, which develops as a result of another disease or condition. The rationale behind using Iron chelation therapy is removing the increased iron burden specifically labile cell iron (LCI) to minimize production of reactive oxygen species (ROS) thereby decreasing cellular and organ damage. Patients most likely to benefit from chelation therapy include those with low or intermediate-1 IPSS risk MDS who have a long-life expectancy and are anticipated to receive more than 20 red blood cell transfusions and/or whose serum ferritin level is >1000 μg/L. Chelation therapy efficacy can be monitored by monitoring trends and levels of serum ferritin.
An iron chelation drug is a type of medication used to remove excess iron from the body. These drugs bind to the excess iron, forming a soluble complex that can be excreted from the body, primarily used in conditions like hemochromatosis and iron overload in patients receiving chronic blood transfusions. Common iron chelators include deferoxamine (Desferal), deferasirox (Exjade), and deferiprone (Ferriprox).
Global Iron Chelation Drug key players include Novartis, Chiesi Group, Sun Pharma, Cipla, Natco Pharma, etc. Global top five manufacturers hold a Revenue Market Share over 35%. Europe accounts for the most Sales Market Share, which have a share over 40%, followed by North America. In terms of product, Deferasirox is the largest segment, with a Revenue Market Share over 90%. And in terms of application, the largest Application is Transfusional Iron Overload, followed by NTDT Caused Iron Overload.
The primary driver of the iron chelation drug market is the increasing prevalence of diseases that cause iron overload, such as thalassemia, sickle cell anemia, and other chronic conditions requiring frequent blood transfusions. As awareness of iron overload and its complications grows, there is a greater demand for effective iron chelation therapies. Additionally, advancements in drug formulation and delivery methods, such as oral chelators, have improved patient compliance and convenience, further driving market growth.
One of the main challenges in the iron chelation drug market is the potential side effects and toxicity associated with chelation therapy. Adverse effects, such as gastrointestinal issues, kidney impairment, and hearing loss, can limit the long-term use of these drugs and affect patient adherence. Furthermore, the high cost of iron chelation therapy, especially newer oral formulations, can be a significant barrier for patients and healthcare systems, particularly in low- and middle-income countries.
This report is a detailed and comprehensive analysis for global Iron Chelation Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Iron Chelation Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Iron Chelation Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Iron Chelation Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Iron Chelation Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Iron Chelation Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Iron Chelation Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Chiesi Group, Sun Pharma, Cipla, Natco Pharma, Taro Pharm, Gland Pharma, Pfizer, Fresenius, Teva, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Iron Chelation Drug market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Deferasirox
Deferoxamine
Deferiprone
Market segment by Application
Transfusional Iron Overload
NTDT Caused Iron Overload
Major players covered
Novartis
Chiesi Group
Sun Pharma
Cipla
Natco Pharma
Taro Pharm
Gland Pharma
Pfizer
Fresenius
Teva
Alkem Laboratories
Alembic
Dr Reddy's Laboratories
Hikma Pharmaceuticals
Apotex
Viatris
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Iron Chelation Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Iron Chelation Drug, with price, sales quantity, revenue, and global market share of Iron Chelation Drug from 2020 to 2025.
Chapter 3, the Iron Chelation Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Iron Chelation Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Iron Chelation Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Iron Chelation Drug.
Chapter 14 and 15, to describe Iron Chelation Drug sales channel, distributors, customers, research findings and conclusion.
In a healthy body, when the stores of iron are sufficient, the intestines reduce the absorption of this mineral from food and drink to prevent its levels from rising too high. People with iron overload disorders absorb more iron than usual from food or supplements. The body cannot excrete the extra iron fast enough, so it continues to build up. The body stores it in organ tissue, mainly in the liver, as well as the heart and the pancreas. There are several types of iron overload disorder. Hereditary hemochromatosis is a primary condition that has a genetic component. People can also have secondary hemochromatosis, which develops as a result of another disease or condition. The rationale behind using Iron chelation therapy is removing the increased iron burden specifically labile cell iron (LCI) to minimize production of reactive oxygen species (ROS) thereby decreasing cellular and organ damage. Patients most likely to benefit from chelation therapy include those with low or intermediate-1 IPSS risk MDS who have a long-life expectancy and are anticipated to receive more than 20 red blood cell transfusions and/or whose serum ferritin level is >1000 μg/L. Chelation therapy efficacy can be monitored by monitoring trends and levels of serum ferritin.
An iron chelation drug is a type of medication used to remove excess iron from the body. These drugs bind to the excess iron, forming a soluble complex that can be excreted from the body, primarily used in conditions like hemochromatosis and iron overload in patients receiving chronic blood transfusions. Common iron chelators include deferoxamine (Desferal), deferasirox (Exjade), and deferiprone (Ferriprox).
Global Iron Chelation Drug key players include Novartis, Chiesi Group, Sun Pharma, Cipla, Natco Pharma, etc. Global top five manufacturers hold a Revenue Market Share over 35%. Europe accounts for the most Sales Market Share, which have a share over 40%, followed by North America. In terms of product, Deferasirox is the largest segment, with a Revenue Market Share over 90%. And in terms of application, the largest Application is Transfusional Iron Overload, followed by NTDT Caused Iron Overload.
The primary driver of the iron chelation drug market is the increasing prevalence of diseases that cause iron overload, such as thalassemia, sickle cell anemia, and other chronic conditions requiring frequent blood transfusions. As awareness of iron overload and its complications grows, there is a greater demand for effective iron chelation therapies. Additionally, advancements in drug formulation and delivery methods, such as oral chelators, have improved patient compliance and convenience, further driving market growth.
One of the main challenges in the iron chelation drug market is the potential side effects and toxicity associated with chelation therapy. Adverse effects, such as gastrointestinal issues, kidney impairment, and hearing loss, can limit the long-term use of these drugs and affect patient adherence. Furthermore, the high cost of iron chelation therapy, especially newer oral formulations, can be a significant barrier for patients and healthcare systems, particularly in low- and middle-income countries.
This report is a detailed and comprehensive analysis for global Iron Chelation Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Iron Chelation Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Iron Chelation Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Iron Chelation Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Iron Chelation Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Iron Chelation Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Iron Chelation Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Chiesi Group, Sun Pharma, Cipla, Natco Pharma, Taro Pharm, Gland Pharma, Pfizer, Fresenius, Teva, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Iron Chelation Drug market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Deferasirox
Deferoxamine
Deferiprone
Market segment by Application
Transfusional Iron Overload
NTDT Caused Iron Overload
Major players covered
Novartis
Chiesi Group
Sun Pharma
Cipla
Natco Pharma
Taro Pharm
Gland Pharma
Pfizer
Fresenius
Teva
Alkem Laboratories
Alembic
Dr Reddy's Laboratories
Hikma Pharmaceuticals
Apotex
Viatris
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Iron Chelation Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Iron Chelation Drug, with price, sales quantity, revenue, and global market share of Iron Chelation Drug from 2020 to 2025.
Chapter 3, the Iron Chelation Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Iron Chelation Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Iron Chelation Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Iron Chelation Drug.
Chapter 14 and 15, to describe Iron Chelation Drug sales channel, distributors, customers, research findings and conclusion.
Table of Contents
141 Pages
- 1 Market Overview
- 2 Manufacturers Profiles
- 3 Competitive Environment: Iron Chelation Drug by Manufacturer
- 4 Consumption Analysis by Region
- 5 Market Segment by Type
- 6 Market Segment by Application
- 7 North America
- 8 Europe
- 9 Asia-Pacific
- 10 South America
- 11 Middle East & Africa
- 12 Market Dynamics
- 13 Raw Material and Industry Chain
- 14 Shipments by Distribution Channel
- 15 Research Findings and Conclusion
- 16 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
